Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Arg2-derived peptide vaccine-induced changes in gene expression in Pan02 tumors

ABSTRACT: Investigate changes in the gene expression in the tumor upon vaccination with an Arg2-derived peptide in a murine tumor model (Pan02)

ORGANISM(S): Mus musculus

PROVIDER: GSE212500 | GEO | 2022/11/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Arg2-derived peptide vaccine-induced changes in gene expression in Pan02 tumors

Project description:Arg2-derived peptide vaccine-induced changes in gene expression in Pan02 tumors

| PRJNA875646 | ENA

Changes in gene expression in Pan02 tumors after TGFb-derived peptide vaccination

Project description:To investigate changes in the tumor microenvironment at a gene expression level induced by TGFb-derived peptide vaccination in a murine model of PDAC (Pan02)

2022-12-14 | GSE206764 | GEO

Changes in gene expression in Pan02 tumors after TGFb-derived peptide vaccination

Project description:Changes in gene expression in Pan02 tumors after TGFb-derived peptide vaccination

| PRJNA852083 | ENA

Gene expression in Pan02 tumors from mice that were either untreated, treated with a TGFb vaccine, with an anti-IL-6R blocking antibody or the combination of the TGFb vaccine and an anti-IL-6R blocking antibody

Project description:To investigate changes in the tumor microenvironment at a gene expression level induced by IL-6R blockade and compare it to treatment with the TGFb vaccine in a murine model of PDAC (Pan02)

2025-01-08 | GSE263363 | GEO

RNASeq of Arg2 gRNA or scrambled gRNA CRISPR'd Tregs

Project description:The aim of the study was to analyze the transcriptional profile of Tregs following CRISPR deletion of Arg2

2019-11-08 | GSE140031 | GEO

Effect of Arg2 overexpression on murine liver gene expression profiles

Project description:We demonstrate the effects of Arg2 overexpression on murine liver gene expression by high-throughput RNA sequencing

2019-02-06 | GSE126134 | GEO

TWEAK-treated time course in Pan02 cells

Project description:Tumor necrosis factor-related weak inducer of apoptosis, TWEAK, is a TNF superfamily member that mediates signaling through its receptor fibroblast growth factor inducible-14, Fn14. In tumor cell lines, TWEAK induces proliferation, survival and NF-kappaB signaling and gene expression that promote tumor growth and suppress antitumor immune responses. Anti-TWEAK antibody, RG7212, inhibits tumor growth in vivo with decreases in pathway activation markers and modulation of tumor, blood and spleen immune cell composition. Candidate response prediction markers, including Fn14, have been identified in mouse models. Phase I pharmacodynamic data from patients are consistent with preclinical results. TWEAK:Fn14 signaling is upregulated in human cancer and pathway activation induces tumor proliferation and survival signaling. Blockade with anti-TWEAK mAb, RG7212, inhibits tumor growth in multiple models in mice. TWEAK induces changes that suppress anti-tumor immune responses and RG7212 blocks these effects resulting in changes in tumor immune cell composition and decreases in cytokines that promote immunosuppression. Antitumor efficacy in mice was observed in a range of Fn14 expressing models with pathway activation and expressing either wild-type or mutant p53, BRAF or KRAS suggesting both a patient selection strategy and potential broad clinical applicability. Preclinical mechanism of action hypotheses are supported by Phase I clinical data, with decreases in proliferation markers and increased tumor T cell infiltration. Pan02 cells untreated or treated with 1090-TW (TWEAK) for 4 hours, 8 hours, or 24 hours. Four replicates for each condition were performed.

2013-10-04 | E-GEOD-42047 | biostudies-arrayexpress

The effects of Arginase 2 (Arg2) knockout on chronic hypoxia-induced pulmonary hypertension

Project description:Increased arginase 2 protein expression is associated with endothelial dysfunction and pulmonary hypertension, likely by impairing NO production secondary to substrate availability. Hypoxia induces arginase 2 protein expression contributing to pulmonary vascular cell proliferation. Non-specific arginase inhibitors have been shown to prevent experimental pulmonary hypertension in animal models. RNA was isolated from whole lung tissue from adult (12-14 weeks) arginase 2 wild type and KO mice exposed to 21% O2 or 10% O2 for 28 days. Animals were sacrificed and the lungs collected and stored at -80°C . Total RNA was isolated with Trizol and used for RNA-seq. RNA-seq results indicate notable differentially expressed gene transcripts were evident in the Arg2 WT and Arg2 KO lungs. There were 25 unique transcripts identified (>2-fold change, p < 0.001) between the normoxia and hypoxia-exposed Arg2 WT. Interestingly, there was significantly greater differences in the Arg2 KO mice exposed to hypoxia compared to normoxia, with 188 unique transcripts (>2-fold change, p < 0.001) identified by RNA seq.

2020-05-01 | GSE131425 | GEO

Profiling the inflammatory signatures of bulk MC38, Pan02 and KPC tumors from wild-type mice and Sirpα-KO mice before and after radiation therapy

Project description:The inflammatory gene expression profile in MC38, Pan02 and KPC tumors from wild-type mice and Sirpα-KO mice before and after radiation was analyzed by nCounter Analysis System using nCounter Mouse Immunology kit including 561 immunology-related mouse genes .

2021-04-19 | GSE149882 | GEO

Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Colorectal Cancer and Breast Cancer

Project description:Interventions: Survivin-2B peptide vaccination at a dose of 0.1mg every 2 weeks Survivin-2B peptide vaccination at a dose of 1.0mg every 2 weeks Survivin-2B peptide vaccination at a dose of 10mg every 2 weeks Primary outcome(s): Evaluation of adverse effect Study Design: Parallel Non-randomized

| 2616404 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data